Castle Biosciences: TissueCypher Changed Care for 96% in Study
Friendswood – October 12, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.
The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.
TissueCypher and clinicopathologic scoring agreed only slightly in the multi-center cohort
The cohort study (P5192) compared TissueCypher with the Progression in Barrett's (PIB) clinicopathologic approach and found only slight agreement (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk. The PIB score classified 31% as low risk and 69% as intermediate/high risk.